PART I . Overview We are a clinical-stage biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. We believe immunotherapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering immunotherapies that are safer, more effective and more broadly accessible. Although Chimeric Antigen Receptor T-cells (CAR-Ts) have shown benefits to date, they have primarily been constraine...
Q2 FY2026 — expected 2026-08-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076876 | EDGAR | 116K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029150 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022048 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010610 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0000950170-22-004573 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-266932 | EDGAR | 63K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105064 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067100 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123442 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094120 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057007 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062930 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042402 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018782 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025099 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017455 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009732 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-23 | 0001193125-26-063955 | EDGAR | 52K words |
| 2025-12-08 | 0001193125-25-311276 | EDGAR | — |
| 2025-11-05 | 0001193125-25-266866 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105015 | EDGAR | — |
| 2025-05-28 | 0001193125-25-129522 | EDGAR | — |
| 2025-05-14 | 0001193125-25-119506 | EDGAR | — |
| 2025-05-08 | 0001193125-25-116023 | EDGAR | — |
| 2025-03-20 | 0001193125-25-058978 | EDGAR | — |
| 2025-02-27 | 0001193125-25-039316 | EDGAR | — |
| 2024-12-12 | 0001193125-24-275844 | EDGAR | — |
73 total filings indexed. 46 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001786205 |
| Ticker | ACLX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ACLX (~200 tokens, structured JSON with cryptographic provenance)